Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (193)	3/25/2002 6:59:23 PM
From: Michael Young	Read Replies (2) \| Respond to of 508

I just don't understand all the attention paid to near-term actimmune sales. 90% of the sales will disappear instantly if the Phase III data released in November doesn't prove the drug is effective against IPF. Conversely, I find no reason to believe that sales won't increase substantially if the trial is a success. Maybe the theory is that sales are trending down now because DRs and patients are finding the drug ineffective? MIKE